Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Melanoma 4Skin Neoplasms 2Neoplasm Metastasis 2Carcinoma, Squamous Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Kidney Neoplasms 1Eyelid Squamous Cell Carcinoma 1Cutaneous Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Merkel Cell 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Anus Neoplasms 1Adenocarcinoma 1

Interventions

figitumumab 2vandetanib 1cemiplimab 1brigatinib 1alpha-2'-deoxythioguanosine 1Vinorelbine 1Paclitaxel 1Gemcitabine 1Erlotinib Hydrochloride 1Docetaxel 1Crizotinib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Large Cell × cemiplimab × Clear all
NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡